ClinicalTrials.gg
CompletedNCT03491228Updated Dec 28, 2018Results posted

Anaemetro I.V. Infusion 500mg Drug Use Investigation

An observational study in Anaerobic Infection, Infectious Enterocolitis and Amebic Dysentery, sponsored by Pfizer. Completed. Per ClinicalTrials.gov, last updated 2018-12-28.

Sponsored by Pfizer · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
107
Sex
All
01

Study summary

Secondary Data Collection Study; safety and effectiveness of Anaemetro under Japanese medical practice

02

Conditions studied

  • Anaerobic Infection
  • Infectious Enterocolitis
  • Amebic Dysentery
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who satisfy all of the inclusion criteria are subject to this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have not used metronidazole (injection) in the past, and have been given this drug for treatment of anaerobic infection, infectious enterocolitis, or amebic dysentery. Patients who have used metronidazole (oral agent and vaginal tablet) in the past are eligible, and should not be excluded from this study.

Exclusion criteria

Exclusion Criteria:

  • No exclusion criteria are set out in this study.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
107 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Drug Reaction (ADR)

    An adverse drug reaction (ADR) was any untoward medical occurrence attributed to ANAEMETRO Intravenous infusion in a participant who received ANAEMETRO Intravenous infusion. A serious ADR was an ADR resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Relatedness to ANAEMETRO Intravenous infusion was assessed by the physician.

    Time frame: Maximum 8 weeks

Secondary outcomes

  1. Clinical Response Rate

    Clinical response of ANAEMETRO Intravenous infusion was evaluated comprehensively at the completion of the observation period, being assessed as "effective," "not effective," or "indeterminate" by the physician based on clinical symptoms. Clinical response rate, which was defined as the percentage of participants evaluated as "effective" over the total number of assessable effectiveness analysis population, was presented along with the corresponding 2-sided 95% CI.

    Time frame: Maximum 8 weeks

  2. Clinical Response Rates by Target Diseases

    Clinical response of ANAEMETRO Intravenous infusion was evaluated comprehensively at the completion of the observation period, being assessed as "effective," "not effective," or "indeterminate" by the physician based on clinical symptoms. Clinical response rate, which was defined as the percentage of participants evaluated as "effective" over the total number of assessable effectiveness analysis population, was presented along with the corresponding 2-sided 95% CI. Participants assessed as "effective" by the following target diseases were counted to assess whether they contribute to the clinical response: anaerobic infection, infectious enterocolitis, amebic dysentery, and the infection with both infectious enterocolitis and amebic dysentery.

    Time frame: Maximum 8 weeks

07

Results

Posted Dec 28, 2018

Participant flow

Participant flow — Overall Study
MilestoneANAEMETRO Intravenous Infusion (Metronidazole)
Started107
Completed107
Not completed0

Outcome measures

PrimaryNumber of Participants With Adverse Drug Reaction (ADR)

An adverse drug reaction (ADR) was any untoward medical occurrence attributed to ANAEMETRO Intravenous infusion in a participant who received ANAEMETRO Intravenous infusion. A serious ADR was an ADR resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Relatedness to ANAEMETRO Intravenous infusion was assessed by the physician.

Time frame:
Maximum 8 weeks
Reported as:
Number · Participants
Number of Participants With Adverse Drug Reaction (ADR)
ParticipantsANAEMETRO Intravenous Infusion (Metronidazole)
ADR7
Serious ADR1
SecondaryClinical Response Rate

Clinical response of ANAEMETRO Intravenous infusion was evaluated comprehensively at the completion of the observation period, being assessed as "effective," "not effective," or "indeterminate" by the physician based on clinical symptoms. Clinical response rate, which was defined as the percentage of participants evaluated as "effective" over the total number of assessable effectiveness analysis population, was presented along with the corresponding 2-sided 95% CI.

Time frame:
Maximum 8 weeks
Reported as:
Number · Percentage of Participants
Clinical Response Rate
Percentage of ParticipantsANAEMETRO Intravenous Infusion (Metronidazole)
Clinical Response Rate95.8 (89.6 to 98.8)
SecondaryClinical Response Rates by Target Diseases

Clinical response of ANAEMETRO Intravenous infusion was evaluated comprehensively at the completion of the observation period, being assessed as "effective," "not effective," or "indeterminate" by the physician based on clinical symptoms. Clinical response rate, which was defined as the percentage of participants evaluated as "effective" over the total number of assessable effectiveness analysis population, was presented along with the corresponding 2-sided 95% CI. Participants assessed as "effective" by the following target diseases were counted to assess whether they contribute to the clinical response: anaerobic infection, infectious enterocolitis, amebic dysentery, and the infection with both infectious enterocolitis and amebic dysentery.

Time frame:
Maximum 8 weeks
Reported as:
Number · Percentage of Participants
Clinical Response Rates by Target Diseases
Percentage of ParticipantsANAEMETRO Intravenous Infusion (Metronidazole)
Anaerobic infection (n=64)excluding IND(n=10)93.8 (84.8 to 98.3)
Infectious enterocolitis (n=21) excluding IND(n=2)100.0 (83.9 to 100.0)
Amebic dysentery (n=7)100.0 (59.0 to 100.0)
Infectious enterocolitis + amebic dysentery (n=3)100.0 (29.2 to 100.0)

Adverse events

Collected over Maximum 8 weeks. Non-serious events are listed at a 1.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ANAEMETRO Intravenous Infusion (Metronidazole)3/107 (2.8%)11/107 (10.3%)2/107 (1.9%)
Most frequent serious events
Most frequent serious events
EventANAEMETRO Intravenous Infusion (Metronidazole)
Disseminated intravascular coagulationBlood and lymphatic system disorders2/107
Liver disorderHepatobiliary disorders2/107
Bronchopulmonary aspergillosisInfections and infestations1/107
Clostridium difficile infectionInfections and infestations1/107
PneumoniaInfections and infestations1/107
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders1/107
Respiratory failureRespiratory, thoracic and mediastinal disorders1/107
Cholecystitis acuteHepatobiliary disorders1/107
Multiple organ dysfunction syndromeGeneral disorders1/107
Most frequent other events
Most frequent other events
EventANAEMETRO Intravenous Infusion (Metronidazole)
NauseaNervous system disorders2/107

Baseline characteristics

A total of 107 participants were enrolled in this study. There was no participant excluded from the baseline analysis.

Age, Customized
Age, Customized(Participants)ANAEMETRO Intravenous Infusion (Metronidazole)
<15 years0
≥15 and <65 years40
≥65 years67
Sex/Gender, Customized
Sex/Gender, Customized(Participants)ANAEMETRO Intravenous Infusion (Metronidazole)
Male69
Female38
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)ANAEMETRO Intravenous Infusion (Metronidazole)
Target Diseases
Target Diseases(Participants)ANAEMETRO Intravenous Infusion (Metronidazole)
Anaerobic infection74
Infectious enterocolitis23
Amebic dysentery7
Infectious enterocolitis + amebic dysentery3
08

Study locations

No study locations are listed for this record.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2015 to primary completion in Aug 2017, 25 months.

Results were first posted in Dec 2018, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2018
First posted
Apr 9, 2018
StartActual
Jul 2015
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Results first posted
Dec 28, 2018
Last update
Dec 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03491228
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 9, 2018
Start date
Jul 2015
Primary completion
Aug 2017
Completion
Aug 2017
Results posted
Dec 28, 2018
Last update
Dec 28, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion